Gene editing treatment for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of retinitis pigmentosa (a condition causing gradual vision loss).
- You must be 18 years or older.
- Genetic testing must show you have a change in the RHO gene that the drug targets, and no other harmful eye gene changes.
- Your vision in the study eye (usually the worse eye) must be within a specific range, from seeing hand movements to about 20/63 on an eye chart.
- You must agree to use effective birth control during the study and for 1 year after treatment.
- Be willing to sign a consent form and follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests an experimental gene therapy for people with a specific type of retinitis pigmentosa caused by a change in the RHO gene. The therapy is given in multiple doses to see if it is safe and helpful.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This Phase 1/2 study tests a gene therapy treatment (BS01) in people with retinitis pigmentosa to try to improve or preserve vision. You may be a candidate if your vision in at least one eye is quite limited and you haven’t had certain gene therapies before.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.